Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00093613 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

NIH

Sponsor class

Conditions

Adult Anaplastic Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Giant Cell Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor

Interventions

DRUG: sorafenib tosylate
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)